CACTUS COMMUNICATIONS IMAGE: RESEARCHERS FROM CHINA HAVE DEVELOPED A NOVEL CONJUGATE THAT CAN SUPPRESS THE GROWTH OF K-RAS MUTANT PANCREATIC TUMORS WITH HIGH EFFICACY. CREDIT: JOURNAL OF PHARMACEUTICAL ANALYSIS Often undetected until it has progressed to an advanced stage, pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer. The K-Ras mutant pancreatic cancer is one of...
A protein involved in cholesterol metabolism plays a previously unknown role in suppressing the body’s natural immune defenders in and around pancreatic tumors, research led by the University of Michigan Rogel Cancer Center finds. ApoE, an apolipoprotein known to play roles in cardiovascular disease and Alzheimer’s, is elevated in the blood of people with pancreatic...
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE ANINDYA BAGCHI, PH.D., ASSOCIATE PROFESSOR IN THE TUMOR INITIATION AND MAINTENANCE PROGRAM AT SANFORD BURNHAM PREBYS. view more CREDIT: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Scientists at Sanford Burnham Prebys Medical Discovery Institute have uncovered a novel drug target, a protein called PPP1R1B, that stops the deadly spread of...
Research conducted on human pancreatic tumors transplanted in mice reveals promising results, Tel Aviv University researchers say AMERICAN FRIENDS OF TEL AVIV UNIVERSITY Pancreatic cancer is resistant to all current treatments. Patients have extremely poor chances of surviving for five years after being diagnosed. A new Tel Aviv University study finds that a small molecule...
New Rochelle, NY, August 10, 2017—A new study of patients who underwent curative surgical removal of a pancreatic ductal adenocarcinoma showed that two of the nine preoperative factors analyzed were strongly predictive of poor prognosis regardless of the tumor stage. Preoperative assessment of these prognostic biomarkers might help in planning treatment strategies to improve patient outcomes,...
